News from viacyte, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Feb 03, 2016, 23:59 ET
ViaCyte logo.

ViaCyte Acquires Rights to BetaLogics Assets, Expanding and Extending Industry-Leading Portfolio for Stem Cell-Derived Approaches to Type 1 Diabetes

 ViaCyte, Inc., a leading, privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy...

Jan 06, 2016, 09:00 ET
ViaCyte logo.

ViaCyte to Present at Biotech Showcase 2016 in San Francisco

 ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the...

Nov 17, 2015, 09:00 ET
ViaCyte logo.

ViaCyte to Present at IDF World Diabetes Congress 2015

 ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the...

Nov 16, 2015, 06:00 ET
ViaCyte logo.

ViaCyte Licenses Cell Differentiation Technology to Takara Bio Inc.

 ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the...

Oct 15, 2015, 09:00 ET
ViaCyte logo

ViaCyte to Present at 14th Annual BIO Investor Forum

ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the...

Sep 24, 2015, 09:00 ET
ViaCyte logo.

ViaCyte to Present at Upcoming Healthcare Events

 ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the...

Sep 10, 2015, 09:00 ET
ViaCyte logo.

ViaCyte Announces the Publication of a Report on Macroencapsulated Stem Cell-Derived Insulin-Producing Cells and the Issuance of Three Patents

 ViaCyte, Inc., a privately-held regenerative medicine company with the first stem cell-derived islet replacement therapy for the treatment of...

Jul 29, 2015, 09:00 ET
ViaCyte logo.

ViaCyte Announces Second Clinical Trial Site at University of Alberta

Dr. James Shapiro, who led the team that developed the "Edmonton Protocol," will be lead investigator at the Canadian site  ViaCyte, Inc.,...

Jun 16, 2015, 09:00 ET
ViaCyte logo.

ViaCyte to Present Plenary Lecture at ISSCR 2015 Annual Meeting

 ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the...

May 14, 2015, 09:00 ET
ViaCyte logo

ViaCyte to Present at London Regenerative Medicine Network and The World Stem Cells and Regenerative Medicine Congress 2015

ViaCyte, Inc., a privately-held regenerative medicine company with the first stem cell-derived islet replacement therapy for the treatment of...

May 11, 2015, 09:00 ET
ViaCyte logo.

ViaCyte to Present at Cavendish Global Health Impact Forum

 ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the...

Apr 23, 2015, 09:00 ET
ViaCyte logo.

ViaCyte to Present at GTCbio 2015 Diabetes Summit

ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the...

Mar 17, 2015, 09:00 ET
ViaCyte logo.

ViaCyte to Present at ARM's Third Annual Regen Med Investor Day

 ViaCyte, Inc., a privately-held regenerative medicine company with the first stem cell-derived islet replacement therapy for the treatment of...

Mar 03, 2015, 09:00 ET
ViaCyte logo.

ViaCyte to Present at JDRF TypeOneNation Research Summit

SAN DIEGO and BETHESDA, Md., March 3, 2015 /PRNewswire/-- ViaCyte, Inc., a privately-held regenerative medicine company with the first stem...

Feb 25, 2015, 09:00 ET
ViaCyte logo

ViaCyte to Present at 35th Annual Cowen and Company Health Care Conference

ViaCyte, Inc., a privately-held regenerative medicine company with the first stem cell-derived islet replacement therapy for the treatment of...

Feb 23, 2015, 09:00 ET
ViaCyte logo.

ViaCyte to Present at Two San Diego Events: Biocom's Global Life Science Partnering Conference and UCSD Diabetes Public Forum

 ViaCyte, Inc., a privately-held regenerative medicine company with the first stem cell-derived islet replacement therapy for the treatment of...

Jan 12, 2015, 09:15 ET
ViaCyte logo.

JDRF Honors Current and Former ViaCyte Team with Top Scientific Excellence Award

 ViaCyte and JDRF announced today that the current and former ViaCyte team are being recognized by JDRF for their pioneering work in developing...

Jan 08, 2015, 09:00 ET
ViaCyte logo.

ViaCyte Receives Clearance from Health Canada for Diabetes Clinical Trial

ViaCyte, Inc., a privately-held regenerative medicine company with the first stem cell-derived islet replacement therapy for the treatment of...

Dec 22, 2014, 09:00 ET
ViaCyte logo.

ViaCyte to Present at Biotech Showcase in San Francisco

 ViaCyte, Inc., a privately-held regenerative medicine company with the first stem cell-derived islet replacement therapy for the treatment of...

Dec 18, 2014, 09:00 ET
ViaCyte logo.

Study Further Validates Cell Therapy Approach to Reverse Type 1 Diabetes

ViaCyte, Inc. announced today a preclinical study published online in Cell Stem Cell that describes a novel approach to replace the...